FLT3/FGFR dual kinase inhibitor MAX-40279

{
  "id": "MLC-T-ONC-013634",
  "term": "FLT3/FGFR dual kinase inhibitor MAX-40279",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration of FLT3/FGFR dual kinase inhibitor MAX-40279, this agent binds to and inhibits both FGFR and FLT3, including FLT3 mutant forms, which results in the inhibition of FGFR/FLT3-mediated signal transduction pathways. This inhibits proliferation in FGFR/FLT3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases, is upregulated in many tumor cell types. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias. They both play key roles in cellular proliferation and survival.",
  "synonyms": [
    "FLT3/FGFR kinase inhibitor MAX-40279"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/flt3-fgfr-dual-kinase-inhibitor-max-40279/"
}